Skip to main content
SpringerLink
Log in

Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy

  • Chapter
Improving Prognosis for Kidney Disorders

  • 85 Accesses

Abstract

Diabetic nephropathy is a progressive disease and a leading cause of end stage renal disease. However, the decline in glomerular filtration rate (GFR) varies substantially between patients, ranging from 2 to 20 ml/min/year. Thus, identification of predictors of progression in diabetic nephropathy is of importance. Plasma total homocysteine (tHcy) rises with urinary albumin rate in diabetes, and plasminogen activator inhibitor-1 (PAI-1) has been correlated to increased matrix accumulation in various glomerulopathies. The aim of the present prospective observational cohort study was to evaluate the importance of baseline tHcy and PAI-1 as predictors of the rate of decline in GFR. At baseline tHcy and PAI-1 were measured in 157 type 1 diabetic patients with diabetic nephropathy (92 males, age 41 ± 10 years, diabetes duration 28 ± 8 years, GFR (median (range)) 80 (23–143) ml/min/1.73 m2). Hereafter, GFR was measured yearly with a plasma clearance technique for at least 3 years, median 7 (range 3.0 to 8.3) years. The mean rate of decline in GFR was 3.7 (0.3) ml/min/year. A linear regression analysis revealed a borderline significant relation between rate of decline in GFR and tHcy (p=0.069) and PAI-1 (p=0.087), respectively. Analyzing rate of decline in GFR and ter-tiles of tHcy and PAI-1, increasing levels of tHcy was correlated with a faster decline in GFR, p=0.025, whereas PAI-1 was not. However, after adjustment for other risk factors for progression of nephropathy, i.e. progression promoters, in a multiple linear regression analysis, neither tHcy nor PAI-1 was independent predictors of rate of decline in GFR. Our study demonstrates a relation between plasma tHcy and the rate of decline in GFR. Plasma tHcy and PAI-1 were, however, not found to be independent predictors of progression in diabetic nephropathy after adjustment for other well established progression promoters.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T: Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25: 496–501, 1983

    Article  PubMed  CAS  Google Scholar 

  2. Rossing P, Rossing K, Jacobsen P, Parving H-H: Unchanged incidence of diabetic nephropathy in IDDM patients. Diab 44: 739–43, 1995

    Article  CAS  Google Scholar 

  3. Parving H-H, Osterby R, Ritz E: Diabetic nephropathy, in Brenner BM (ed): The Kidney, Chap 39. Philadelphia, 2000, pp 1731–73.

    Google Scholar 

  4. Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 36: 383–8, 1976

    Article  PubMed  CAS  Google Scholar 

  5. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR: A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 20: 457–61, 1981

    Article  PubMed  CAS  Google Scholar 

  6. Viberti GC, Bilous RW, Mackintosh D, Keen H: Monitoring glomerular function in diabetic nephropathy. Am J Med 74: 25664, 1983

    Article  Google Scholar 

  7. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274: 1049–1057, 1995

    Article  PubMed  CAS  Google Scholar 

  8. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346: 1395–8, 1995

    Article  PubMed  CAS  Google Scholar 

  9. Amesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE: Serum total homocysteine and coronary heart disease. Int J Epidemiol 24: 704–9, 1995

    Article  Google Scholar 

  10. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva A, Gonzalez-Sastre F, Blanco-Vaca F: Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 41: 684–93, 1998

    Article  PubMed  CAS  Google Scholar 

  11. Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M, Amiral J, Schmidt AM, Fiehn W, Ziegler R, Wahl P, Nawroth PP: Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 21: 841–8, 1998

    Article  PubMed  CAS  Google Scholar 

  12. Hamsten A, Eriksson P: Fibrinolysis and atherosclerosis. Bailliers Clinical Haematology 8: 345–63, 1995

    Article  CAS  Google Scholar 

  13. Nakamura T, Tanaka N, Higuma N, Kazama T, Kobayashi I, Yokota S: The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy. J Am Soc Nephrol 7: 2434–44, 1996

    PubMed  CAS  Google Scholar 

  14. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219–27, 2000

    Article  PubMed  CAS  Google Scholar 

  15. Fogo AB: Progression and potential regression of glomerulosclerosis. Kidney Int 59: 804–19, 2001

    Article  PubMed  CAS  Google Scholar 

  16. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Le-cerf L, Poirier O, Danilov S, Parving H-H: Lack of relationship between an insertion/deletion polymorphism in the angiotensinI-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diab 44: 489–94, 1995

    Article  CAS  Google Scholar 

  17. Tamow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Boelskifte S, Borch-Johnsen K, Parving H-H: Insertion/deletion polymorphism in the angiotensin-l-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 38: 798–803, 1995

    Article  Google Scholar 

  18. Parving H-H, Andersen AR, Smidt UM, Svendsen PAa: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet i: 1175–9, 1983

    Google Scholar 

  19. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E, Kastrup J, Lefevre P, Mathiesen ER, Feldt-Rasmussen B, Schmitz A, Viberti GC: Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 9: 85–95, 1985

    PubMed  Google Scholar 

  20. te Poele-Pothoff MT, van den BM, Franken DG, Boers GH, Jakobs C, de Kroon IF, Eskes TK, Trijbels JM, Blom HJ: Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 32 (Pt 2): 218–20, 1995

    Google Scholar 

  21. Bröchner-Mortensen J, Rödbro P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36: 35–45, 1976

    Article  PubMed  Google Scholar 

  22. Feldt-Rasmussen B, Dinesen B, Deckert M: Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45: 539–44, 1985

    Article  PubMed  CAS  Google Scholar 

  23. Breyer JA, Bain P, Evans JK, Nahman NS, Lewis E, Cooper ME, McGill JB, Berl T, The Collaborative Study Group: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50: 1651–8, 1996

    Article  PubMed  CAS  Google Scholar 

  24. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH: Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminurie. Kidney Int 55: 308–14, 1999

    Article  PubMed  CAS  Google Scholar 

  25. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 338: 1042–50, 1998

    Article  PubMed  CAS  Google Scholar 

  26. Targher G, Bertolini L, Zenari L, Cacciatori V, Muggeo M, Faccini G, Zoppini G: Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes. Diabetes Care 23: 524–8, 2000

    Article  PubMed  CAS  Google Scholar 

  27. Pavia C, Ferrer I, Valls C, Artuch R, Colome C, Vilaseca MA: Total homocysteine in patients with type 1 diabetes. Diabetes Care 23: 84–7, 2000

    Article  PubMed  CAS  Google Scholar 

  28. Stabler SP, Estacio R, Jeffers BW, Cohen JA, Allen RH, Schrier RW: Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism 48: 1096–101, 1999

    Article  PubMed  CAS  Google Scholar 

  29. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 52: 10–20, 1997

    Article  PubMed  CAS  Google Scholar 

  30. Fogo A: The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. American Journal of Kidney disease 35: 179–88, 2000

    Article  CAS  Google Scholar 

  31. Jensen T, Feldt-Rasmussen B, Bjerre-Knudsen J, Deckert T: Features of endothelial dysfunction in early diabetic nephropathy. Lancet i: 461–3, 1989

    Google Scholar 

  32. Auwerx J, Bouillon R, Collen D, Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8: 68–72, 1998

    Google Scholar 

  33. Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G: PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diab 43: 426–9, 1994

    Article  CAS  Google Scholar 

  34. Tamow, L., Stehouwer, C. D. A., Emeis, J. J., Poirier, O., Cambien, F., Hansen, B. V., and Parving, H: H. Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic nephropathy. Nephrol Dial Transplant 15: 625–30, 2000

    Article  Google Scholar 

  35. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A: Modulation of plasminogen-activator inhibitor-1 in-vivo–a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51: 164–72, 1997

    Article  PubMed  CAS  Google Scholar 

  36. Rossing P: Promotion, prediction, and prevention of progression in diabetic nephropathy. Diabetic Med 15: 900–19, 1998

    Article  PubMed  CAS  Google Scholar 

  37. Hovind, P., Rossing, P., Tarnow, L., Smidt, U. M., and Parving, H.-H. Progression of diabetic nephropathy. Kidney Int 51: 7029, 2001

    Google Scholar 

Download references

Authors
  1. Peter Hovind MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lise Tarnow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Rossing DMSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Coen D. A. Stehouwer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jef J. Emeis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans-Henrik Parving DMSc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Long Island College Hospital, Brooklyn, New York, USA

    Morrell Michael Avram

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Hovind, P., Tarnow, L., Rossing, P., Stehouwer, C.D.A., Emeis, J.J., Parving, HH. (2002). Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy. In: Avram, M.M. (eds) Improving Prognosis for Kidney Disorders. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-1848-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-1848-6_11

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-6164-5

  • Online ISBN: 978-94-017-1848-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation